Mosaic ImmunoEngineering (CPMV) Stock Price, News & Analysis

Company Overview

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

Key Stats

• Today's Range: $0.62 to $1.00
• 50-Day Range: $0.64 to $1.00
• 52-Week Range: $0.10 to $1.13
• Volume: 350 shs
• Average Volume: 168 shs
• Market Capitalization: $7.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mosaic ImmunoEngineering Stock Analysis - MarketRank™

Mosaic ImmunoEngineering scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mosaic ImmunoEngineering.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mosaic ImmunoEngineering is -6.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mosaic ImmunoEngineering is -6.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the outstanding shares of Mosaic ImmunoEngineering have been sold short.

Short Interest Ratio / Days to Cover

Mosaic ImmunoEngineering has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mosaic ImmunoEngineering does not currently pay a dividend.

Dividend Growth

Mosaic ImmunoEngineering does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the outstanding shares of Mosaic ImmunoEngineering have been sold short.

Short Interest Ratio / Days to Cover

Mosaic ImmunoEngineering has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Mosaic ImmunoEngineering this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mosaic ImmunoEngineering insiders have not sold or bought any company stock.

Percentage Held by Insiders

80.99% of the stock of Mosaic ImmunoEngineering is held by insiders. A high percentage of insider ownership can be a sign of company health.

CPMV Stock Analysis - Frequently Asked Questions

How have CPMV shares performed this year?

Mosaic ImmunoEngineering's stock was trading at $0.60 at the start of the year. Since then, CPMV stock has increased by 66.7% and is now trading at $1.00.
View the best growth stocks for 2024 here.

How do I buy shares of Mosaic ImmunoEngineering?

Shares of CPMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mosaic ImmunoEngineering own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mosaic ImmunoEngineering investors own include BioNxt Solutions (BNXTF), Defense Metals (DFMTF), C3.ai (AI), Applied Genetic Technologies (AGTC), Agile Therapeutics (AGRX), AgriFORCE Growing Systems (AGRI) and Aeva Technologies (AEVA).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CPMV
• CUSIP: N/A
• CIK: 836564
• Web: www.ptsc.com
• Phone: (657) 208-0890
• Fax: 760-547-2705
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,010,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,180.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.81) per share
• Price / Book: -1.23

Miscellaneous

• Outstanding Shares: 7,240,000
• Free Float: 1,377,000
• Market Cap: $7.24 million
• Optionable: Not Optionable
• Beta: 0.01